Bright Minds Biosciences (DRUG) Accumulated Expenses (2024 - 2025)
Bright Minds Biosciences (DRUG) reported Accumulated Expenses of $392781.8 for Q3 2025, up 1183.36% on a YoY basis from $30605.7 in Q3 2024, and up 1183.36% quarter-over-quarter from $30605.7 in Q3 2024.
Bright Minds Biosciences (DRUG) Accumulated Expenses (2024 - 2025) Analysis & Trends
Bright Minds Biosciences has reported Accumulated Expenses for 2 years, with the latest figure at $392781.8 in Q3 2025.
- For the quarter ending Q3 2025, Accumulated Expenses rose 1183.36% year-over-year to $392781.8; the trailing twelve-month figure through Sep 2025 stood at $392781.8 (up 1183.36% YoY), and the FY2025 full-year result was $392781.8, up 1183.36% from the prior year.
- Accumulated Expenses for Q3 2025 stood at $392781.8, up from $30605.7 in the prior quarter.
- The five-year high for Accumulated Expenses was $392781.8 in Q3 2025, with the low at $30605.7 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Bright Minds Biosciences | 16.28 Bn | 16.22 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 392,781.82 |
| Sep 30, 2024 | 30,605.71 |